KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Debt to Equity (2016)

Historic Debt to Equity for Vertex Pharmaceuticals (VRTX) over the last 6 years, with Q4 2016 value amounting to $0.22.

  • Vertex Pharmaceuticals' Debt to Equity fell 1693.53% to $0.22 in Q4 2016 from the same period last year, while for Dec 2016 it was $0.22, marking a year-over-year decrease of 1693.53%. This contributed to the annual value of $0.22 for FY2016, which is 1693.53% down from last year.
  • According to the latest figures from Q4 2016, Vertex Pharmaceuticals' Debt to Equity is $0.22, which was down 1693.53% from $0.25 recorded in Q3 2016.
  • In the past 5 years, Vertex Pharmaceuticals' Debt to Equity ranged from a high of $0.3 in Q1 2015 and a low of $0.22 during Q4 2016
  • In the last 3 years, Vertex Pharmaceuticals' Debt to Equity had a median value of $0.27 in 2014 and averaged $0.26.
  • Its Debt to Equity has fluctuated over the past 5 years, first soared by 738.66% in 2015, then tumbled by 1693.53% in 2016.
  • Vertex Pharmaceuticals' Debt to Equity (Quarter) stood at $0.27 in 2014, then rose by 0.36% to $0.27 in 2015, then dropped by 16.94% to $0.22 in 2016.
  • Its Debt to Equity stands at $0.22 for Q4 2016, versus $0.25 for Q3 2016 and $0.25 for Q2 2016.